Cipher Capital’s Mersana Therapeutics MRSN Stock Holding History

Cipher Capital’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-482	Closed	-$82K	–	581
2022 Q3	$82K	Buy	+482	New	+$78.3K	0.01%	405

Other funds holding MRSN

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Cipher Capital's MRSN Position: Q4 2022 in Review

Cipher Capital sold out of Mersana Therapeutics (MRSN) in Q4 2022, closing a stake of 482 shares — an estimated $82K sold.

Cipher Capital first reported a position in MRSN in Q3 2022 and held it in 1 quarter. The position peaked at $82K in Q3 2022. 152 funds tracked by Wall St. Rank hold MRSN as of Q4 2022.

Cipher Capital reported no remaining Mersana Therapeutics position as of Q4 2022 after selling out during the quarter.
Cipher Capital sold 482 Mersana Therapeutics shares in Q4 2022, an estimated $82K.
Cipher Capital first reported a position in Mersana Therapeutics in Q3 2022 and held it in 1 quarter.
Cipher Capital's Mersana Therapeutics position peaked at $82K in Q3 2022.
152 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2022.

Based on Cipher Capital's 13F filing for Q4 2022, filed 13 Feb 2023.